Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom

Álvaro Segura, Guillermo León, Chen Yao Su, José María Gutiérrez, Thierry Burnouf

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We have evaluated for the first time the impact of a solvent/detergent (S/D) treatment on the quality and in vivo neutralization potency of horse-derived whole IgG antivenom used in the treatment of viperid snake bite envenoming in Central America. The S/D treatment by 1% tri (n-butyl) phosphate (TnBP) - 1% Triton X-45 at 22-25 °C was applied either on starting plasma or on purified immunoglobulins. The S/D agents were removed from both fractions by extractions with oil. S/D-treated plasma was subjected to caprylic acid precipitation to purify the immunoglobulins. Products were formulated, sterile-filtered, and filled into 10-mL vials, stored at 5 ± 3 °C, and subjected to routine quality controls, SDS-PAGE, determination of anti-Bothrops asper venom antibody titre by ELISA, in vivo B. asper venom-neutralization potency tests, and safety test, comparatively with an antivenom manufactured by caprylic acid fractionation without S/D treatment. Results indicate that these conditions of S/D treatment on purified immunoglobulin yielded an antivenom of high turbidity that induced weight loss in animals. In contrast, antivenom fractionated from the S/D-treated plasma had physico-chemical and biological characteristics indistinguishable from those of the non-S/D-treated antivenom. S/D treatment of horse plasma may be considered to increase the viral safety of antivenoms.

Original languageEnglish
Pages (from-to)306-312
Number of pages7
JournalBiologicals
Volume37
Issue number5
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Antivenins
Detergents
Horses
Immunoglobulin G
Plasmas
Immunoglobulins
Therapeutics
Venoms
Bothrops
Snake Bites
Safety
Central America
Neutralization Tests
Acids
Octoxynol
Turbidity
Fractionation
Antibodies
Quality Control
Quality control

Keywords

  • Antivenom
  • Neutralization
  • Snake bite envenoming
  • Solvent/detergent
  • Viral inactivation

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Bioengineering
  • Immunology and Microbiology(all)
  • Pharmacology

Cite this

Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom. / Segura, Álvaro; León, Guillermo; Su, Chen Yao; Gutiérrez, José María; Burnouf, Thierry.

In: Biologicals, Vol. 37, No. 5, 10.2009, p. 306-312.

Research output: Contribution to journalArticle

Segura, Álvaro ; León, Guillermo ; Su, Chen Yao ; Gutiérrez, José María ; Burnouf, Thierry. / Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom. In: Biologicals. 2009 ; Vol. 37, No. 5. pp. 306-312.
@article{85745bfa99ab46569d71bce57b7d0b8f,
title = "Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom",
abstract = "We have evaluated for the first time the impact of a solvent/detergent (S/D) treatment on the quality and in vivo neutralization potency of horse-derived whole IgG antivenom used in the treatment of viperid snake bite envenoming in Central America. The S/D treatment by 1{\%} tri (n-butyl) phosphate (TnBP) - 1{\%} Triton X-45 at 22-25 °C was applied either on starting plasma or on purified immunoglobulins. The S/D agents were removed from both fractions by extractions with oil. S/D-treated plasma was subjected to caprylic acid precipitation to purify the immunoglobulins. Products were formulated, sterile-filtered, and filled into 10-mL vials, stored at 5 ± 3 °C, and subjected to routine quality controls, SDS-PAGE, determination of anti-Bothrops asper venom antibody titre by ELISA, in vivo B. asper venom-neutralization potency tests, and safety test, comparatively with an antivenom manufactured by caprylic acid fractionation without S/D treatment. Results indicate that these conditions of S/D treatment on purified immunoglobulin yielded an antivenom of high turbidity that induced weight loss in animals. In contrast, antivenom fractionated from the S/D-treated plasma had physico-chemical and biological characteristics indistinguishable from those of the non-S/D-treated antivenom. S/D treatment of horse plasma may be considered to increase the viral safety of antivenoms.",
keywords = "Antivenom, Neutralization, Snake bite envenoming, Solvent/detergent, Viral inactivation",
author = "{\'A}lvaro Segura and Guillermo Le{\'o}n and Su, {Chen Yao} and Guti{\'e}rrez, {Jos{\'e} Mar{\'i}a} and Thierry Burnouf",
year = "2009",
month = "10",
doi = "10.1016/j.biologicals.2009.05.003",
language = "English",
volume = "37",
pages = "306--312",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom

AU - Segura, Álvaro

AU - León, Guillermo

AU - Su, Chen Yao

AU - Gutiérrez, José María

AU - Burnouf, Thierry

PY - 2009/10

Y1 - 2009/10

N2 - We have evaluated for the first time the impact of a solvent/detergent (S/D) treatment on the quality and in vivo neutralization potency of horse-derived whole IgG antivenom used in the treatment of viperid snake bite envenoming in Central America. The S/D treatment by 1% tri (n-butyl) phosphate (TnBP) - 1% Triton X-45 at 22-25 °C was applied either on starting plasma or on purified immunoglobulins. The S/D agents were removed from both fractions by extractions with oil. S/D-treated plasma was subjected to caprylic acid precipitation to purify the immunoglobulins. Products were formulated, sterile-filtered, and filled into 10-mL vials, stored at 5 ± 3 °C, and subjected to routine quality controls, SDS-PAGE, determination of anti-Bothrops asper venom antibody titre by ELISA, in vivo B. asper venom-neutralization potency tests, and safety test, comparatively with an antivenom manufactured by caprylic acid fractionation without S/D treatment. Results indicate that these conditions of S/D treatment on purified immunoglobulin yielded an antivenom of high turbidity that induced weight loss in animals. In contrast, antivenom fractionated from the S/D-treated plasma had physico-chemical and biological characteristics indistinguishable from those of the non-S/D-treated antivenom. S/D treatment of horse plasma may be considered to increase the viral safety of antivenoms.

AB - We have evaluated for the first time the impact of a solvent/detergent (S/D) treatment on the quality and in vivo neutralization potency of horse-derived whole IgG antivenom used in the treatment of viperid snake bite envenoming in Central America. The S/D treatment by 1% tri (n-butyl) phosphate (TnBP) - 1% Triton X-45 at 22-25 °C was applied either on starting plasma or on purified immunoglobulins. The S/D agents were removed from both fractions by extractions with oil. S/D-treated plasma was subjected to caprylic acid precipitation to purify the immunoglobulins. Products were formulated, sterile-filtered, and filled into 10-mL vials, stored at 5 ± 3 °C, and subjected to routine quality controls, SDS-PAGE, determination of anti-Bothrops asper venom antibody titre by ELISA, in vivo B. asper venom-neutralization potency tests, and safety test, comparatively with an antivenom manufactured by caprylic acid fractionation without S/D treatment. Results indicate that these conditions of S/D treatment on purified immunoglobulin yielded an antivenom of high turbidity that induced weight loss in animals. In contrast, antivenom fractionated from the S/D-treated plasma had physico-chemical and biological characteristics indistinguishable from those of the non-S/D-treated antivenom. S/D treatment of horse plasma may be considered to increase the viral safety of antivenoms.

KW - Antivenom

KW - Neutralization

KW - Snake bite envenoming

KW - Solvent/detergent

KW - Viral inactivation

UR - http://www.scopus.com/inward/record.url?scp=69649102234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69649102234&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2009.05.003

DO - 10.1016/j.biologicals.2009.05.003

M3 - Article

C2 - 19540775

AN - SCOPUS:69649102234

VL - 37

SP - 306

EP - 312

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 5

ER -